AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity

…, JN Feige, M Lagouge, L Noriega, JC Milne, PJ Elliott… - Nature, 2009 - nature.com
AMP-activated protein kinase (AMPK) is a metabolic fuel gauge conserved along the evolutionary
scale in eukaryotes that senses changes in the intracellular AMP/ATP ratio 1 . Recent …

[HTML][HTML] Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α

…, F Daussin, N Messadeq, J Milne, P Lambert, P Elliott… - Cell, 2006 - cell.com
Diminished mitochondrial oxidative phosphorylation and aerobic capacity are associated with
reduced longevity. We tested whether resveratrol (RSV), which is known to extend lifespan…

Proteasome inhibitors: a novel class of potent and effective antitumor agents

…, DD Lazarus, J Maas, CS Pien, S Prakash, PJ Elliott - Cancer research, 1999 - AACR
The ubiquitin-proteasome pathway plays a critical role in the regulated degradation of proteins
involved in cell cycle control and tumor growth. Dysregulating the degradation of such …

Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes

…, DA Sinclair, JM Olefsky, MR Jirousek, PJ Elliott… - Nature, 2007 - nature.com
Calorie restriction extends lifespan and produces a metabolic profile desirable for treating
diseases of ageing such as type 2 diabetes 1 , 2 . SIRT1, an NAD + -dependent deacetylase, …

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells

…, P Richardson, D Chauhan, VJ Palombella, PJ Elliott… - Cancer research, 2001 - AACR
Human multiple myeloma (MM) is a presently incurable hematological malignancy, and novel
biologically based therapies are urgently needed. Proteasome inhibitors represent a novel …

[PDF][PDF] Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span

…, A Csiszar, Y Ikeno, D Le Couteur, PJ Elliott… - Cell metabolism, 2008 - cell.com
A small molecule that safely mimics the ability of dietary restriction (DR) to delay age-related
diseases in laboratory animals is greatly sought after. We and others have shown that …

[BOOK][B] Probabilistic number theory I: Mean-value theorems

PDTA Elliott - 2012 - books.google.com
… For an alternative treatment see the author's paper (Elliott [16]). In fact a satisfactory analysis
of the limiting behaviour of the frequencies (10) may be carried out assuming only that the …

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

…, S Stahl, J Adams, DL Esseltine, PJ Elliott… - Journal of Clinical …, 2002 - ascopubs.org
PURPOSE: To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and
pharmacodynamics (PD) of the proteasome inhibitor bortezomib (previously known as PS-…

[HTML][HTML] Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation

…, SM Houten, JC Milne, PD Lambert, C Mataki, PJ Elliott… - Cell metabolism, 2008 - cell.com
The NAD + -dependent deacetylase SIRT1 controls metabolic processes in response to low
nutrient availability. We report the metabolic phenotype of mice treated with SRT1720, a …

Systematic discovery of multicomponent therapeutics

AA Borisy, PJ Elliott, NW Hurst… - Proceedings of the …, 2003 - National Acad Sciences
Multicomponent therapies, originating through deliberate mixing of drugs in a clinical setting,
through happenstance, and through rational design, have a successful history in a number …